Argenica Therapeutics Limited

ASX:AGN Stock Report

Market Cap: AU$82.0m

Argenica Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Argenica Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-14.2%

Buyback Yield

Total Shareholder Yield-14.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Jul 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Apr 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Nov 30
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGN's dividend payments have been increasing.


Dividend Yield vs Market

Argenica Therapeutics Dividend Yield vs Market
How does AGN dividend yield compare to the market?
SegmentDividend Yield
Company (AGN)n/a
Market Bottom 25% (AU)2.7%
Market Top 25% (AU)6.2%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast (AGN) (up to 3 years)n/a

Notable Dividend: Unable to evaluate AGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AGN's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AGN has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 22:55
End of Day Share Price 2024/12/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Argenica Therapeutics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution